Related Experiment Video
Updated: May 31, 2026

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
Published on: July 21, 2023
Involvement of microparticles in diabetic vascular complications
Gala Tsimerman1, Ariel Roguin, Anat Bachar
1Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Abstract:
Type 2 diabetes mellitus (T2DM) is associated with increased coagulability and vascular complications. Circulating microparticles (MPs) are involved in thrombosis, inflammation, and angiogenesis. However, the role of MPs in T2DM vascular complications is unclear. We characterised the cell origin and pro-coagulant profiles of MPs obtained from 41 healthy controls and 123 T2DM patients with coronary artery disease, retinopathy and foot ulcers. The effects of MPs on endothelial cell coagulability and tube formation were evaluated. Patients with severe diabetic foot ulcers expressed the highest levels of MPs originated from platelet and endothelial cells and negatively-charged phospholipid-bearing MPs. MP coagulability, calculated from MP tissue factor (TF) and TF pathway inhibitor (TFPI) ratio, was low in healthy controls and in diabetic retinopathy patients (<0.7) but high in patients with coronary artery disease and foot ulcers (>1.8, p≥0.002). MPs of all T2DM patients induced a more than two-fold increase in endothelial cell TF (antigen and gene expression) but did not affect TFPI levels. Tube networks were longest and most stable in endothelial cells that were incubated with MPs of healthy controls, whereas no tube formation occurred in MPs of diabetic patients with coronary artery disease. MPs of diabetic retinopathy and diabetic foot ulcer patients induced branched tube networks that were unstable and collapsed over time. This study demonstrates that MP characteristics are related to the specific type of vascular complications and may serve as a bio-marker for the pro- coagulant state and vascular pathology in patients with T2DM.
Insights
Microparticles (MPs) in type 2 diabetes mellitus (T2DM) patients vary by vascular complication. MP profiles may indicate coagulability and vascular damage, serving as potential biomarkers for T2DM complications.
Area of Science:
- Cardiovascular Research
- Endocrinology
- Hematology
Background:
- Type 2 diabetes mellitus (T2DM) is linked to heightened blood clotting and vascular issues.
- Circulating microparticles (MPs) play roles in thrombosis, inflammation, and blood vessel formation, but their specific involvement in T2DM vascular complications remains under investigation.
Purpose of the Study:
- To characterize the cellular origin and pro-coagulant properties of MPs in T2DM patients with various vascular complications.
- To assess the impact of these MPs on endothelial cell coagulability and their ability to form vascular networks.
Main Methods:
- Analysis of MP origin (platelet, endothelial cells) and charge from T2DM patients (coronary artery disease, retinopathy, foot ulcers) and healthy controls.
- Quantification of MP coagulability using the tissue factor (TF) and TF pathway inhibitor (TFPI) ratio.
- In vitro assessment of MP effects on endothelial cell TF and TFPI expression and tube formation capacity.
Main Results:
- Patients with severe diabetic foot ulcers showed elevated levels of platelet and endothelial cell-derived MPs, along with negatively charged MPs.
- MP coagulability was significantly higher in T2DM patients with coronary artery disease and foot ulcers compared to healthy controls and those with retinopathy.
- T2DM patient MPs increased endothelial cell TF expression but did not alter TFPI levels, impairing endothelial tube formation and stability.
Conclusions:
- Microparticle characteristics correlate with specific vascular complications in T2DM.
- MPs may serve as valuable biomarkers for assessing the pro-coagulant state and vascular pathology in T2DM patients.
Related Concept Videos
Diabetic Retinopathy
Diabetic Nephropathy
Complications of Diabetes Mellitus
Diabetic Foot Ulcer
Diabetic Neuropathy
Type I Diabetes II: Pathophysiology
